Form 4: Harmony Biosciences CEO Sells Shares After Option Exercise

Harmony Biosciences Holdings, Inc. President and CEO, Jeffrey M. Dayno, exercised stock options and subsequently sold a portion of the acquired common stock under a Rule 10b5-1 trading plan.

Summary

• Jeffrey M. Dayno, President and CEO of Harmony Biosciences Holdings, Inc. (HRMY), reported transactions on December 12, 2025.
• Dayno exercised 20,000 stock options at an exercise price of $8.22 per share.
• Subsequently, Dayno sold a total of 25,933 shares of common stock.
• The sales were executed at a weighted average price of $40.1073 per share, with prices ranging from $40.00 to $40.28.
• These sales were conducted under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Dayno's direct beneficial ownership of common stock is 0 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the transaction was pre-scheduled under a Rule 10b5-1 plan, mitigating concerns of immediate negative sentiment. The exercise of options also indicates prior value creation.

Positives

• The exercise of stock options indicates that the options had intrinsic value, as the exercise price ($8.22) was significantly lower than the sale price ($40.1073).
• The transactions were conducted under a Rule 10b5-1 trading plan, which suggests a pre-scheduled sale rather than a reaction to immediate company news.

Negatives

• The sale of 25,933 shares by a high-ranking insider (President and CEO) could be perceived negatively by investors, potentially signaling a lack of confidence, although mitigated by the 10b5-1 plan.
• The reporting person's direct beneficial ownership of common stock is now 0 shares following these transactions.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report reflects a personal financial decision by a key executive and does not directly relate to broader industry trends or competitive positioning, beyond general market conditions influencing stock value.

Comparison to Industry Standards

• Not applicable for an insider transaction report, as this filing details personal stock transactions of an executive rather than company performance or operational metrics.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal, potentially influencing sentiment, though the pre-arranged 10b5-1 plan mitigates immediate concerns about the timing of the sale.

Key Dates

Keywords

Harmony Biosciences, HRMY, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Jeffrey M. Dayno